Australia: Life Sciences, Biotechnology & Nanotechnology

Australia’s health and life sciences sector is growing rapidly, and with that growth comes a more complex web of legal exposure for the organisations that operate within it. The recent Bartier Perry panel event, Health and Life Sciences: Research Integrity Under the Microscope, explored how failures in data and research integrity translate into real-world risk.

A prisoner made an application to Queensland Corrective Services seeking to have some of her eggs extracted and frozen so that she may undergo ‘assisted reproductive technology’ upon her release from imprisonment.

Health and life sciences is rapidly emerging as a major sector in Australia’s economy, helping to drive innovation, advancements in medical treatments, public health and scientific understanding. However, as the sector grows, driven by unprecedent technological change, the industry faces growing risk of fraud and research misconduct, which can have far-reaching consequences for organisations, corporate reputation and public trust.

Finding into death without inquest: Geoffrey Paul McConachy. Coroners Court of Victoria [COR 2023 005213]

The Mayne Pharma/Cosette battle provides a rare example of how things can go awry in a public company transaction.

This article considers how the area of embryo selection and testing engages ethical and regulatory considerations, and explore what this means for assisted reproductive technology (ART) providers moving forward.

Pharmaceutical manufacturing group, Celgene Corporation and Celgene Pty Ltd (together, "Celgene"), and generic drug companies, Juno Pharmaceuticals ("Juno") and Natco Pharma ("Natco")...

Last week Pfizer filed a lawsuit in a federal court of Australia against respondents Samsung Bioepis, Merck, Sharp & Dohme, Organon, and Arrow, to halt sales of their biosimilar BRENZYS (etanercept).

Last week, a Full Court of the Federal Court of Australia handed down two unanimous decisions on appeal, clearing up some key uncertainties in the application of Australia's patent term extension (PTE) regime.